Tigecycline's Anaerobe Coverage Basics
Tigecycline, a glycylcycline antibiotic, covers most anaerobic bacteria, including Gram-positive anaerobes like Clostridium species and Gram-negative anaerobes like Bacteroides fragilis. It achieves this through broad-spectrum inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit, bypassing common tetracycline resistance mechanisms.[1]
Metronidazole's Anaerobe Coverage Basics
Metronidazole targets obligate anaerobes selectively, excelling against Gram-negative anaerobes (Bacteroides, Fusobacterium) and some protozoa. It works by disrupting DNA synthesis in low-oxygen environments via reductive activation into toxic metabolites.[2] It has limited activity against Gram-positive anaerobes like Clostridium difficile (though used clinically for it) and none against aerotolerant strains like Actinomyces.
Key Differences in Spectrum
- Gram-Negative Anaerobes: Both provide strong coverage, but tigecycline handles Bacteroides strains with elevated MICs better due to its resistance evasion.[1][3]
- Gram-Positive Anaerobes: Tigecycline covers a wider range (Clostridium, Peptostreptococcus, Propionibacterium), while metronidazole is weaker or inactive against many, especially microaerophilic ones.[1][2]
- Scope and Limitations: Tigecycline's coverage is broader overall but static (bacteriostatic), not killing anaerobes outright. Metronidazole is bactericidal against strict anaerobes but fails against facultative or aerotolerant anaerobes and has no aerobic coverage.[3]
| Aspect | Tigecycline | Metronidazole |
|--------|-------------|---------------|
| Gram-Positive Anaerobes | Strong (e.g., Clostridium, Actinomyces) | Variable/weak (e.g., poor vs. Actinomyces) |
| Gram-Negative Anaerobes | Strong (Bacteroides fragilis) | Strong (Bacteroides, Prevotella) |
| Aerotolerant/Microaerophilic | Good | Poor/none |
| Mechanism | Bacteriostatic (ribosomal) | Bactericidal (DNA damage) |
| Resistance Profile | Overcomes efflux/pump resistance | Prone to nitroreductase mutations |
Clinical Use Implications
Tigecycline suits polymicrobial intra-abdominal infections with mixed aerobes/anaerobes (e.g., complicated intra-abdominal infections per FDA approval). Metronidazole fits anaerobic-specific cases like C. difficile colitis or gynecologic infections but pairs with others for broader needs. Tigecycline risks higher mortality in ventilator-associated pneumonia (not anaerobic-focused), limiting its use there.[4]
When to Choose One Over the Other
Use tigecycline for resistant, mixed infections where anaerobes overlap with Enterobacteriaceae. Reserve metronidazole for proven strict anaerobes or cost-sensitive monotherapy (it's cheaper, oral option available). Neither covers all anaerobes fully—test susceptibility for Bacteroides resistance to both.[3]
[1]: Tigecycline prescribing information, FDA
[2]: Metronidazole prescribing information, FDA
[3]: Clinical breakpoints for anaerobes, CLSI M11
[4]: Tigecycline safety review, FDA 2013